HbA1c as a predictor for response of bevacizumab in diabetic macular oedema.
Sadhana SharmaSagun Narayan JoshiPratap KarkiPublished in: BMJ open ophthalmology (2020)
Our study suggests that baseline glycaemic control can affect the treatment outcome of intravitreal bevacizumab in the management of diabetic macular oedema and the response was found to be better in patients with good glycaemic control (low HbA1c).